Cefpiramide
Based on 1 Customer Validation
Cefpiramide (SM-1652) free acid is a semisynthetic cephalosporin with broad-spectrum antibacterial activity. Cefpiramide free acid shows strong antibacterial effect on both gram-positive bacteria and gram-negative bacteria. Cefpiramide free acid is moderately susceptible to β-lactamase.
For research use only. We do not sell to patients.
- Purity : 99.72%
- CAS No.: 70797-11-4
- Formula: C25H24N8O7S2
- Molecular Weight:612.64
-
Storage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Biological Activity
Description
|
β-lactam |
In Vitro
Cefpiramide (0-2048 μg/mL; 16-18 hours) shows good activity to against most non-fermentative Gram-negative bacilli and Enterococci (32 μg/mL with 97% inhibition)[1].
Cefpiramide (0-2048 μg/mL; 16-18 hours) exhibits high effective to against Pseudomonas aeruginosa with MIC[50] and MIC[90] values of 4 μg/mL and 16 μg/mL separately[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:761 bacterial isolates (35 different species of common bacterial pathogens)
-
Concentration:0-2048 µg/mL
-
Incubation Time:16-18 hours
-
Result:Showed broad-spectrum antibacterial activity.
In Vivo
Cefpiramide (25 mg/kg; i.v.; once) reduces bacteria in CSF more than 10[4] CFU/ml[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:New Zealand white male rabbits(2-3 kg)[2].
-
Dosage:25 mg/kg
-
Administration:Intravenous injection; once.
-
Result:Anti-Streptococcus pneumoniae.
Chemical Information
-
CAS No. 70797-11-4
-
Appearance Solid
-
Molecular Weight 612.64
-
Formula C25H24N8O7S2
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](NC(C4=C(O)C=C(C)N=C4)=O)C5=CC=C(O)C=C5)=O)C1=O)O
-
Synonyms
SM-1652 free acid; Wy-44635 free acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (204.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Barry AL, et al. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. J Antimicrob Chemother. 1985 Sep;16(3):315-25. [Content Brief]
[2]. Sato K, et al. Pharmacokinetics and bacteriological efficacies of apalcillin and cefpiramide in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 1984 Oct;26(4):578-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6323 mL | 8.1614 mL | 16.3228 mL | 40.8070 mL |
| 5 mM | 0.3265 mL | 1.6323 mL | 3.2646 mL | 8.1614 mL | |
| 10 mM | 0.1632 mL | 0.8161 mL | 1.6323 mL | 4.0807 mL | |
| 15 mM | 0.1088 mL | 0.5441 mL | 1.0882 mL | 2.7205 mL | |
| 20 mM | 0.0816 mL | 0.4081 mL | 0.8161 mL | 2.0403 mL | |
| 25 mM | 0.0653 mL | 0.3265 mL | 0.6529 mL | 1.6323 mL | |
| 30 mM | 0.0544 mL | 0.2720 mL | 0.5441 mL | 1.3602 mL | |
| 40 mM | 0.0408 mL | 0.2040 mL | 0.4081 mL | 1.0202 mL | |
| 50 mM | 0.0326 mL | 0.1632 mL | 0.3265 mL | 0.8161 mL | |
| 60 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6801 mL | |
| 80 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5101 mL | |
| 100 mM | 0.0163 mL | 0.0816 mL | 0.1632 mL | 0.4081 mL |